Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Pushes Further On Cybersecurity Efforts Despite Limited Resources

Executive Summary

US FDA unveiled multiple cybersecurity-related initiatives, including two memoranda of understandings to launch information sharing organizations and playbook for health-care delivery organizations. The agency is continuing a multi-front attack in the area, despite limited resources.

You may also be interested in...



Cybersecurity Is A ‘Team Sport:’ FDA And MITRE Update Medical Device Cybersecurity Playbook

In collaboration with FDA, MITRE published an updated playbook for medical device cybersecurity preparedness.

Let’s Talk About Cybersecurity: US FDA Wants Feedback On Safety Alerts

The FDA is convening a panel of experts in September to talk about how to craft cybersecurity communications that adequately alert patients about potential vulnerabilities while not creating a panic. The meeting comes as the agency has been putting out a growing number of cybersecurity alerts, including most recently a recall for certain vulnerable Medtronic insulin pumps.

Lack Of Funding Stalls Major US FDA Cybersecurity Initiative

A public-private partnership board long touted by top US FDA officials to help address cybersecurity threats has hit a funding wall. The agency received less than half of what it asked for in the FY 2019 budget for its digital efforts, including its cybersecurity strategy, leading it to make some tough choices.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT123390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel